NCCN VERSION 2 2015

NCCN Guidelines Version 2.2015 Breast Cancer

NCCN Guidelines Index Breast Cancer Table of Contents Discussion

a systematic review. Clin Breast Cancer 2006;7:386-395. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17239263 . 587. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 2006;106:1000-1006. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16444747 . 588. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet 2010;375:377-384. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0140673609619644 . 589. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:1831-1838. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16549824 . 590. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46-53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12506169 . 591. Limentani SA, Brufsky AM, Erban JK, et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007;25:1232-1238. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17296975 .

579. Bleicher RJ, Morrow M. Inflammatory breast cancer: Still poorly characterized. The Dawood/Cristofanilli article reviewed. Oncology 2007;21:679-680. Available at: http://www.cancernetwork.com/breast- cancer/content/article/10165/61508 . 580. Nguyen DM, Sam K, Tsimelzon A, et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 2006;12:5047-5054. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16951220 . 581. Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009;50:231-238. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19164229 . 582. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008;26:786-790. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18258987 . 583. Fleming RY, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol 1997;4:452-461. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9309333 . 584. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321-329. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9225950 . 585. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin

Breast Cancer 2004;4:415-419. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15023242 .

586. Kim T, Lau J, Erban J. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes:

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-109